logo
India's ultra rich are diversifying wealth with private equity, AIFs and global bets

India's ultra rich are diversifying wealth with private equity, AIFs and global bets

Time of India6 hours ago

India's ultra-wealthy families are moving beyond wealth preservation to embrace riskier, more diversified investment strategies, with a growing preference for global markets and alternative asset classes, according to the EY–Julius Baer report titled The Indian Family Office Playbook, released Thursday.
The report captures a structural shift underway in India's family office ecosystem, which has grown from just 45 family offices in 2018 to more than 300 today. While 25% of these offices still prioritise capital preservation, a growing number are now allocating capital across private equity, venture capital, global real estate, and other non-traditional assets.
'India's family office ecosystem is at an inflection point where wealth preservation alone is no longer enough,' said Surabhi Marwah, Co-leader, Private Tax and Partner, People Advisory Services – Tax at
EY
India. 'Families now seek efficiency, transparency, and global access, all of which require a more structured approach. At the same time, navigating tax and cross-border regulatory frameworks is becoming central to how these offices function and plan ahead.'
Play Video
Pause
Skip Backward
Skip Forward
Unmute
Current Time
0:00
/
Duration
0:00
Loaded
:
0%
0:00
Stream Type
LIVE
Seek to live, currently behind live
LIVE
Remaining Time
-
0:00
1x
Playback Rate
Chapters
Chapters
Descriptions
descriptions off
, selected
Captions
captions settings
, opens captions settings dialog
captions off
, selected
Audio Track
Picture-in-Picture
Fullscreen
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Text
Color
White
Black
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Opaque
Semi-Transparent
Text Background
Color
Black
White
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Opaque
Semi-Transparent
Transparent
Caption Area Background
Color
Black
White
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Transparent
Semi-Transparent
Opaque
Font Size
50%
75%
100%
125%
150%
175%
200%
300%
400%
Text Edge Style
None
Raised
Depressed
Uniform
Drop shadow
Font Family
Proportional Sans-Serif
Monospace Sans-Serif
Proportional Serif
Monospace Serif
Casual
Script
Small Caps
Reset
restore all settings to the default values
Done
Close Modal Dialog
End of dialog window.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Here's The Average Price of a 6-Hour Gutter Upgrade in Austin
Homebuddy.com
Read More
Undo
From preservation to performance
Many of these family offices, especially those catering to first-generation entrepreneurs, are led by younger wealth owners with higher risk tolerance and deeper sector expertise.
The report notes that more than half of the surveyed family offices have allocated over 50% of their portfolios to growth-oriented assets, with over a quarter allocating more than 20% to private equity and venture capital alone.
Live Events
While traditional allocations to public equities, bonds, and cash remain part of core strategies, they are increasingly being complemented by exposure to portfolio management services (PMS), alternative investment funds (AIFs), private credit, REITs, InvITs, and even art.
India's alternative investment industry, comprising PMS and AIFs, is on track to exceed ₹100 lakh crore in assets under management by 2030, the report estimates.
Recent regulatory and tax changes are making this space more attractive: SEBI has eased investment norms for Category II AIFs, and the 2025 Union Budget clarified that the sale of securities by AIFs would be taxed as capital gains, reducing compliance burdens.
Global reach, local strength
Indian family offices are also rapidly globalising, driven by both necessity and opportunity. With Liberalised Remittance Scheme (LRS) outflows rising from $18.8 billion in 2019–20 to $31.7 billion in 2023–24, Indian UHNIs are increasingly investing across borders—in private equity funds in the U.S., real estate in Europe, and venture capital across Asia.
Cross-border partnerships are becoming more common as family offices collaborate with global peers to gain access to a broader range of opportunities and diversify risk. At the same time, India's own regulatory ecosystem is evolving to support this ambition, with GIFT City emerging as a preferred base for family office operations seeking international exposure and tax efficiency.
'The era of one-size-fits-all investment is over,' the report states. 'Sophisticated, tailored wealth strategies are becoming essential, particularly for younger, tech-savvy founders as well as legacy industrial families navigating succession and sustainability.'
Structuring for complexity
Alongside asset diversification, Indian family offices are investing in governance, succession planning, and institutionalisation.
According to the study, 59% of families have implemented wills or constitutions, and 19% have set up structures like trusts or LLPs. This reflects a growing awareness of the importance of structured transitions in preserving legacy and continuity.
There's also growing interest in impact investing—not just as a tool for philanthropy, but to align capital with long-term values and sustainability goals.
In this context, family offices are increasingly engaging professional advisors and leveraging digital platforms to manage complexity. As wealth spreads across geographies and generations, families are are navigating agile, compliant, and transparent structures that can respond to global risks and opportunities alike.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Altimmune's stock plummets over 60% as liver drug falls short in trial
Altimmune's stock plummets over 60% as liver drug falls short in trial

Time of India

time22 minutes ago

  • Time of India

Altimmune's stock plummets over 60% as liver drug falls short in trial

Altimmune's stock (NASDAQ: ALT) plunged roughly 60–64% in pre-market trading today after it announced mixed results from its mid-stage (IMPACT Phase 2b) trial evaluating its liver drug, pemvidutide , for metabolic dysfunction-associated steatohepatitis (MASH). The drug showed promising results in reducing liver fat and achieving MASH resolution, but failed to deliver strong statistical evidence for fibrosis improvement—a key benchmark in this disease area. What is the current stock price of Altimmune? As of June 26, 2025 , Altimmune is trading at $7.71 per share . This price represents a significant pullback from its recent highs, though it remains above its 52-week low. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Join new Free to Play WWII MMO War Thunder War Thunder Play Now Undo Current price: $7.71 52-week high: $11.16 52-week low: $3.55 Market cap: Estimated between $558 million to $625 million Also Read: US stock futures rise: Dow, S&P 500, and Nasdaq edge higher as Nvidia, BlackBerry, and QuantumScape rally Did pemvidutide meet its primary endpoint? Yes. The trial hit its primary goal: resolution of MASH without worsening liver fibrosis. At 24 weeks: Live Events 59.1% of patients on the 1.2 mg dose saw MASH resolution 52.1% achieved resolution on the 1.8 mg dose Only 19.1% on placebo met this benchmark These results were statistically significant and well above expectations, positioning pemvidutide as a serious contender in the MASH space. Also Read: Intel layoffs 2025: Design engineers, software architects lose jobs - these key divisions are next What about weight loss and secondary benefits? Altimmune also highlighted significant weight loss among trial participants: 5.0% weight loss at 1.2 mg 6.2% at 1.8 mg , compared to 1.0% in placebo This positions pemvidutide alongside other GLP-1 class weight-loss drugs, a category currently generating high investor and consumer interest. Why did the stock crash despite positive results? The issue lies with the fibrosis endpoint. While there were improvements, the trial didn't reach statistical significance in its primary analysis of fibrosis reduction—a major goal in MASH treatment. Though an AI-assisted analysis showed 30.6% of patients had ≥60% reduction in fibrosis (vs. 8.2% placebo), it wasn't enough to reassure investors looking for definitive progress in this area. Are analysts still bullish on Altimmune? Yes, despite the sell-off, Wall Street remains optimistic about Altimmune's long-term prospects. The stock currently holds a "Strong Buy" rating from analysts. That suggests potential upside of nearly 190% from the current price level, assuming pemvidutide regains investor confidence in later trials. What are the short-term stock trends for ALT? Technically, ALT has been highly volatile and is currently trading in the mid-range of its 52-week band . Short-term charts show neutral-to-bearish signals , with some analysts recommending caution until the stock finds support or stabilizes. What is MASH treatment? MASH, short for Metabolic dysfunction-associated steatohepatitis, is the new name for what was previously called NASH (Non-Alcoholic Steatohepatitis). It's a serious form of fatty liver disease that occurs when fat builds up in the liver and causes inflammation and liver cell damage, potentially leading to fibrosis, cirrhosis, or even liver cancer. What's next for Altimmune and pemvidutide? Altimmune will hold an investor webcast to discuss results and plans to meet the FDA for an End-of-Phase 2 meeting by late 2025. A Phase 3 trial is still under consideration. FAQs: What caused Altimmune stock to crash after the MASH trial? The stock crashed after its MASH drug failed to show strong results in improving liver fibrosis. Is Altimmune still moving forward with pemvidutide? Yes, the company plans to meet the FDA and may start a Phase 3 trial.

Invicta Diagnostic raises Rs 6 crore in pre-IPO round
Invicta Diagnostic raises Rs 6 crore in pre-IPO round

Time of India

time23 minutes ago

  • Time of India

Invicta Diagnostic raises Rs 6 crore in pre-IPO round

Mumbai-based Invicta Diagnostic on Thursday said it has raised Rs 6 crore from marquee investors in its pre-IPO funding round. The funding round was led by Grobiz SME Opportunities Fund with participation from prominent angel investors, the company said in a statement. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Ingin Tahu Tentang Diagnosis Limfoma? Dapatkan Info Selengkapnya Limfoma Baca Undo Invicta Diagnostic provides a one-stop solution for pathology and radiology testing services , including imaging and clinical laboratory. It has seven diagnostic centres and one centralised laboratory across the Mumbai Metropolitan Region. It offers comprehensive radiology and pathology solutions under the brand name 'PC Diagnostics'.

Why NBA players earn significantly more than NFL players?
Why NBA players earn significantly more than NFL players?

Time of India

time37 minutes ago

  • Time of India

Why NBA players earn significantly more than NFL players?

The NBA and NFL dominate American sports, yet their compensation structures differ significantly. Despite the NFL's higher overall revenue, NBA players consistently earn more individually, owing to various structural and operational factors. In the 2024-25 season, NBA players receive an average salary of £11.91 million, whilst NFL players earn between £2.8 million and £3.2 million annually. The disparity becomes more evident in median salaries, with NBA players at £3.8 million compared to NFL players at £860,000. The significant difference in team sizes plays a crucial role - NFL teams maintain 53 players, whilst NBA rosters contain 15 players. Additionally, the NBA allocates a larger portion of its revenue to player salaries, with its salary cap structure facilitating substantial individual contracts. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Become a Sanomentology™️ Practitioner Today. Sanomentology Learn More Undo NBA compensation continues breaking records, with Stephen Curry earning £55.76 million this year, and Jaylen Brown securing a £304 million contract. NFL stars like Patrick Mahomes and Dak Prescott receive substantial contracts, yet Mahomes' £450 million contract spans ten years, resulting in lower annual earnings than many NBA players. Reason behind NFL's lower salaries Several elements contribute to lower NFL salaries: larger rosters, shorter career spans due to physical demands, non-guaranteed contracts with performance-based incentives, and less international marketability compared to NBA players. Live Events Whilst American football remains the country's preferred sport, basketball players enjoy significantly higher individual earnings, supported by global appeal, smaller team sizes, and guaranteed contracts.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store